DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Public ClinicalTrials.gov record NCT07472517. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein. Participants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Study identification
- NCT ID
- NCT07472517
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 670 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 12, 2026
- Primary completion
- Sep 8, 2028
- Completion
- Jul 29, 2029
- Last update posted
- Aug 18, 2026
2026 – 2029
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Infirmary Cancer Care | Mobile | Alabama | 36607 | Not yet recruiting |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | Not yet recruiting |
| Bioresearch Partner - Hialeah Hospital | Hialeah | Florida | 33013 | Recruiting |
| Emory University | Atlanta | Georgia | 30322 | Recruiting |
| Norton Cancer Institute, Downtown | Louisville | Kentucky | 40202 | Not yet recruiting |
| Pikeville Medical Center | Pikeville | Kentucky | 41501 | Not yet recruiting |
| Epic Medical Research - Monroe | Monroe | Louisiana | 71201 | Not yet recruiting |
| Ochsner Medical Center | New Orleans | Louisiana | 70121 | Not yet recruiting |
| Epic Medical Research - Shreveport | Shreveport | Louisiana | 71105 | Not yet recruiting |
| University of Maryland School of Medicine | Baltimore | Maryland | 21201 | Recruiting |
| Veterans Affairs Ann Arbor Healthcare System | Ann Arbor | Michigan | 48105 | Not yet recruiting |
| HCA MidAmerica Division, Inc. | Kansas City | Missouri | 64132 | Recruiting |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | Not yet recruiting |
| Cape Fear Valley Cancer Center | Fayetteville | North Carolina | 28303 | Not yet recruiting |
| AHN Cancer Institute - Allegheny General | Pittsburgh | Pennsylvania | 15212 | Recruiting |
| Baptist Cancer Center - Memphis | Memphis | Tennessee | 38120 | Recruiting |
| University of Wisconsin | Madison | Wisconsin | 53792 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 228 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07472517, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07472517 live on ClinicalTrials.gov.